Tumor vaccines are a promising form of cancer immunotherapy, but difficulties such as neo-antigen identification, activation of immune cells, and tumor infiltration prevent their clinical breakthrough. Interestingly, nanotechnology-based photothermal therapy (PTT) has great potential to overcome these barriers. Previous studies have shown that serum exosomes (hEX) from hyperthermia-treated tumor-bearing mice displayed an array of patient-specific tumor-associated antigens (TAAs), and strong immunoregulatory abilities in promoting dendritic cell (DC) differentiation and maturation. Here, we developed a tumor vaccine (hEX@BP) by encapsulating black phosphorus quantum dots (BPQDs) with exosomes (hEX) against a murine subcutaneous lung cancer model. In comparison with BPQDs alone (BP), hEX@BP demonstrated better long-term PTT performance, greater elevation of tumor temperature and tumor targeting efficacy in vivo. Vaccination with hEX@BP in combination with PTT further demonstrated an outstanding therapeutic efficacy against established lung cancer, and promoted the infiltration of T lymphocytes into the tumor tissue. Our findings demonstrated that hEX@BP might be an innovative cancer photo-nanovaccine that offers effective immuno-PTT against cancers.
About The Expert
Quan Liu
Taojian Fan
Yuanyuan Zheng
Sheng-Li Yang
Zhiqiang Yu
Yanhong Duo
Yuhua Zhang
Dickson Adah
Lulin Shi
Zhe Sun
Dou Wang
Jianlei Xie
Hong Wu
Zongze Wu
Chenchen Ge
Lijun Qiao
Chaoying Wei
Luodan Huang
Qiaoting Yan
Qinhe Yang
Shiyun Bao
Li-Ping Liu
Han Zhang
References
PubMed